What does Lisata Therapeutics do and what are its main business segments?

What were the key takeaways from Lisata Therapeutics’s earnings call?

What is the market's earnings forecast for Lisata Therapeutics next quarter?

What is Lisata Therapeutics's latest dividend and current dividend yield?

Did Lisata Therapeutics beat or miss consensus estimates last quarter?

What is Lisata Therapeutics's gross profit margin?

What were the key takeaways from Lisata Therapeutics's earnings call?

What guidance did Lisata Therapeutics's management provide for the next earnings period?

- **Financial Stability**: Operating expenses down 17.3% YoY to $4.4 million; $19M cash runway to Q1 2027.
- **Clinical Momentum**: ASCEND trial Cohort A shows 4 complete responses; CENDIFOX pancreatic cancer resection rate 50%.
- **Strategic Expansion**: Catalent ADC partnership with preclinical success; GATC AI drug discovery alliance identifies 2026 candidates.
- **Phase III Challenges**: ASCEND Phase III funding requires pharma partners; stock underperformance despite positive data.


**【CEO Summary Section】**
- Announced strategic alliance with GATC Health to leverage AI for drug discovery and new indications.
- Entered nonexclusive license agreement with Catalent for certepetide use in ADCs, with preclinical data showing enhanced tumor targeting.
- Anticipated Phase III trial for ASCEND contingent on capital acquisition, with FDA-endorsed protocol finalized.
- GBM trial enrollment on track at 2/3 of target 30 patients, with completion expected in 2026.

**【CFO Financial Commentary】**
- Q3 2025 operating expenses: $4.4 million (17.3% YoY decrease), driven by R&D (-22.9%) and G&A (-12.1%) savings.
- Net loss of $4.2 million; cash balance $19 million, supporting operations into Q1 2027.
- Expense reductions achieved through optimized trial costs, consulting cuts, and staff reductions.

**【CMO Clinical Update】**
- ASCEND trial: Cohort A (95 pts) showed 4 complete responses vs. 0 in control; Cohort B (63 pts) demonstrated improved PFS and OS. Final data Q1 2026.
- CENDIFOX: 50% R0 resection rate in pancreatic cancer, 70% pathological response, 60% 2-year OS. Additional data pending.
- iLSTA: Combining certepetide with durvalumab in pancreatic cancer showed enhanced immune response; final data Q1 2026.
- Qilu Pharmaceutical's China trial for metastatic pancreatic cancer nearing completion, data expected 2026-2027.

**【Q&A Highlights】**
- CENDIFOX next data release timing uncertain due to investigator control; GBM trial enrollment 2/3 complete.
- Cash runway excludes Phase III costs; seeking pharma partners to share funding burden.
- Stock underperformance attributed to macro biotech headwinds and limited trading float.
- Exploring nonexclusive licensing to expand certepetide applications, with multiple candidates in pipeline.


Lisata Therapeutics, Inc.(LSTA)-20251107-2025 Q3 Earnings call transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

LSTA

LSTA fundamentals

You can ask Aime